Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 128Melanoma 65Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 53Lung Neoplasms 51Triple Negative Breast Neoplasms 47Neoplasm Metastasis 46Breast Neoplasms 42Neoplasms 39Colorectal Neoplasms 34Carcinoma, Renal Cell 30Head and Neck Neoplasms 29Endometrial Neoplasms 29Ovarian Neoplasms 27Carcinoma, Transitional Cell 23Urinary Bladder Neoplasms 21Stomach Neoplasms 18Carcinoma 16Pancreatic Neoplasms 15Uterine Cervical Neoplasms 14Esophageal Neoplasms 13Brain Neoplasms 13Recurrence 12Sarcoma 11Hodgkin Disease 11Carcinoma, Squamous Cell 11Carcinoma, Hepatocellular 11Cholangiocarcinoma 10Skin Neoplasms 9Esophageal Squamous Cell Carcinoma 9

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3pembrolizumab 2cabozantinib 2sodium thiosulfate 1relacorilant 1fludarabine phosphate 1cemiplimab 1Nivolumab 1Ipilimumab 1Interleukin-13 1Fluorodeoxyglucose F18 1Floxuridine 1Dexamethasone 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adrenocortical Carcinoma × pembrolizumab × 90 days × Clear all
NCT06066333 2026-04-15

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
12 enrolled
Endocrine

Adrenocortical Carcinoma

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡